251 related articles for article (PubMed ID: 11752443)
1. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.
Jiang X; Buxbaum JN; Kelly JW
Proc Natl Acad Sci U S A; 2001 Dec; 98(26):14943-8. PubMed ID: 11752443
[TBL] [Abstract][Full Text] [Related]
2. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
4. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
6. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
7. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
8. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
9. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.
Quintas A; Vaz DC; Cardoso I; Saraiva MJ; Brito RM
J Biol Chem; 2001 Jul; 276(29):27207-13. PubMed ID: 11306576
[TBL] [Abstract][Full Text] [Related]
10. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.
Hammarström P; Jiang X; Hurshman AR; Powers ET; Kelly JW
Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16427-32. PubMed ID: 12351683
[TBL] [Abstract][Full Text] [Related]
11. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
12. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Miller SR; Sekijima Y; Kelly JW
Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of the multistep aggregation pathway of human transthyretin.
Sun X; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6201-E6208. PubMed ID: 29915031
[TBL] [Abstract][Full Text] [Related]
14. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
Hurshman AR; White JT; Powers ET; Kelly JW
Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
[TBL] [Abstract][Full Text] [Related]
16. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
[TBL] [Abstract][Full Text] [Related]
17. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
19. Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy.
Ferreira P; Sant'Anna R; Varejão N; Lima C; Novis S; Barbosa RV; Caldeira CM; Rumjanek FD; Ventura S; Cruz MW; Foguel D
PLoS One; 2013; 8(12):e82484. PubMed ID: 24358189
[TBL] [Abstract][Full Text] [Related]
20. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers.
Lai Z; McCulloch J; Lashuel HA; Kelly JW
Biochemistry; 1997 Aug; 36(33):10230-9. PubMed ID: 9254621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]